In today’s highly competitive academic world, are we losing sight of the real goal of biomedical research in our rush to secure funding and embrace the latest technologies?

It’s often difficult to target pancreatic cancer cells while sparing healthy tissue – but a new therapy concept not only makes this possible, but also enhances the potential effectiveness of adjuvant treatments

When genetics yielded unsatisfactory answers about pancreatic cancer’s persistent survival, researchers looked beyond the genome – and found telling epigenetic changes

A new immunotherapy approach shows that engineered T cells are able to penetrate into pancreatic tumors and directly attack the cancer

The epithelial-to-mesenchymal transition in pancreatic cancer may play a role in its resistance to treatment – and inhibiting it may improve treatment efficacy

Pancreatic cancer is tough to understand, diagnose and treat. Undeterred researchers are on a quest to crack the case.

The human immunodeficiency virus has evaded the best efforts of vaccine developers for over three decades.

The vast majority of experimental cancer drugs fail during the later stages of clinical development

Sitting Down With… Julian Solway MD, Walter L. Palmer Distinguished Service Professor - Medicine and Pediatrics, Director - Institute for Translational Medicine, Dean for Translational Medicine, University of Chicago, USA.

Making grant application processes tougher can have an unexpected and dramatic effect on the demographics of applicants. Let’s not force young investigators to fall at the first hurdle.